Articles

Elsevier,

Epidemics, Volume 47, June 2024

To understand how best to help patients and improve health during an epidemic it is necessary to have good modelling techniques and protocols.
Elsevier,

Forensic Science International: Animals and Environments, Volume 5, June 2024

This study introduces an innovative method using DNA barcodes to accurately identify species, addressing the critical issue of trafficking invaluable medicinal plants like Trillium govanianum.
Elsevier,

Journal of Pharmaceutical Analysis, 2024, 101022, ISSN 2095-1779

This study developed four deep learning models to identify potential Alzheimer's disease treatments from traditional Chinese medicine, specifically the Kaixinsan formula. The models successfully predicted compounds that showed significant anti-Alzheimer's activities in various experimental validations.

Elsevier,

Bone Reports, Volume 21, June 2024

This article looks at complications that arise from combinations of Alzheimers and osteoporosis in mouse models
Elsevier,

The Lancet Healthy Longevity, Volume 5, June 2024

This article supports SDG 3 by showing that using an interactive mHealth application can reduce dementia risk factors in populations who are underserved and at increased risk.
Elsevier,

Biomarkers in Neuropsychiatry, Volume 10, June 2024

This investigation aimed to understand preclinical biomarker and genetic Alzheimer’s disease research participation in underrepresented groups to facilitate greater diversity in future biomarker research and clinical trials.
Elsevier,

IBRO Neuroscience Reports, Volume 16, June 2024

This article summarizes current biomarkers, available treatments, and future therapeutic approaches for Alzheimer's disease, discussing drug targets like Amyloid β, Tau Protein, and various other mechanisms. Additionally, it highlights the historical use of Estradiol, outcomes of trials with antioxidants and omega-3 fatty acids, and ongoing clinical trials, providing a comprehensive overview of the evolving landscape in AD research and treatment.
Elsevier,

Molecular and Cellular Neuroscience, Volume 129, June 2024

Neurological disorders affect approximately one billion people worldwide, with significant disability and mortality impacts, and this review explores how Heparan sulfate proteoglycans (HSPGs) promote Tau fibril formation and tangles in Alzheimer's disease, and the potential role of tunnelling nanotubes (TNTs) in the intercellular transport of Tau and Amyloid β proteins, suggesting that HSPGs may influence TNT formation in neurodegenerative conditions.
Elsevier,

Brain Research, Volume 1832, June 2024

Recent research on Alzheimer's disease (AD) suggests that microglia, immune cells in the brain, may play a beneficial role in early disease stages but become harmful in later stages due to various spatial, temporal, and transcriptional factors. Understanding the phenotypic heterogeneity and multiple states of microglia could lead to advancements in personalized medicine and improved treatment outcomes for AD patients.
Elsevier,

Neurochemistry International, Volume 176, June 2024

This study finds that impaired cellular immune dysfunction in AD patients was significantly correlated with abnormal MRS, and neuroimmune dysfunction may contribute to the pathogenesis of AD and alter the metabolism of neurotransmitters such as aspartic acid and MI in the brains of AD patients.

Pages